A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)

This is a phase 2, multicenter study to determine the safety and efficacy of ICT-107 in treating a type of brain tumor called Glioblastoma Multiforme (GBM).  ICT-107 is an immunotherapy in which the patient's immune response will be stimulated to kill the tumor cells.

Principal Investigator: James M. Markert, M.D., Ph.D.

The purpose of this study is to evaluate the safety and potential benefits of CERE-120 in the treatment of Parkinson's disease.  CERE-120 is an experimental drug that consists of an adeno-associated virus (AAV) that was engineered to carry the human gene for neurturin, a neurotrophic (growth) factor. Similar to other growth factors (such as GDNF), neurturin is capable of restoring function and protecting brain cells from further damage. The virus used in CERE-120 is not known to cause disease in people.

Principal Investigator: Barton L. Guthrie, MD

The purpose of this study is to evaluate the potential benefits of CERE-110 in the treatment of Alzheimer's disease. CERE-110 is an experimental drug that is designed to help nerve cells in the brain function better. CERE-110 uses a virus to transfer a gene that makes Nerve Growth Factor (NGF), a protein that may make nerve cells in the brain healthier and protect them from dying. The virus used in CERE-110 does not cause disease in people. CERE-110 has been carefully studied in laboratory animals and is in the early stages of being tested in people.

Principal Investigator: Barton L. Guthrie, MD 

Treatment of Lumbar Spinal Stenosis With X-STOP® PEEK Spacer in Moderately Symptomatic Patients

This prospective, multicenter longitudinal five-year study of X-STOP PEEK implant usage in lumbar spinal stenosis patients is designed to supplement pre-market safety and effectiveness data with information on longer-term device performance in a population of patients with moderately impaired physical function at preoperative baseline (i.e., an "indicated" population) who elect to undergo X-STOP PEEK surgery.       

Principal Investigator: M.R. Chambers, DVM, MD